Comparative Efficacy and Safety of De-escalation, Abbreviation, and Standard Potent P2Y12 Inhibitor–Based Dual Antiplatelet Therapy Strategies After Acute Coronary Syndrome: A Network Meta-Analysis

Abstract Background Potent P2Y12 inhibitor–based dual antiplatelet therapy (DAPT) is the default antiplatelet strategy after acute coronary syndrome (ACS), though de-escalation to clopidogrel-based DAPT and abbreviated DAPT followed by potent P2Y12 inhibitor monotherapy are increasingly adopted to mitigate bleeding risk. However, their relative efficacy and safety remain uncertain. Methods Network meta-analyses of randomized controlled trials were performed to compare three guideline-endorsed strategies: (1) short-term potent P2Y12 inhibitor–based DAPT de-escalation to clopidogrel-based DAPT, (2) Abbreviated DAPT followed by potent P2Y12 inhibitor monotherapy, and (3) standard 12-month potent P2Y12 inhibitor–based DAPT. Primary efficacy endpoint was major adverse cardiovascular events (MACE). Secondary efficacy endpoints included all-cause mortality, cardiovascular mortality, myocardial infarction, stent thrombosis, and stroke. Primary safety endpoint was major bleeding. The key net clinical endpoint was net adverse clinical events (NACE). PROSPERO (CRD420251144892) Results Seven randomized controlled trials involving 20,673 patients were included. Both the de-escalation and abbreviation strategies significantly reduced major bleeding (RR 0.43, 95% CI 0.25-0.74, p=0.002; and RR 0.43, 95% CI 0.33-0.58, p<0.001, respectively) and NACE (RR 0.54, 95% CI 0.41-0.70, p<0.001; and RR 0.72, 95% CI 0.61-0.84, p<0.001, respectively) without increasing MACE or other ischemic outcomes. Indirect comparison indicated that de-escalation vs abbreviation strategies demonstrated comparable MACE, NACE and bleeding outcomes. Conclusions Following ACS, both de-escalation to clopidogrel-based DAPT and abbreviated DAPT followed by potent P2Y12 inhibitor monotherapy effectively reduce bleeding risk without compromising ischemic protection. Given that the only available comparison between the two simplified strategies was indirect and showed comparable MACE and NACE outcomes, further research is warranted to determine the optimal individualized approach.

Authors

Institutions

Publication Details

Journal
European Heart Journal Open
Published
2026-10-13
DOI
https://doi.org/10.1093/ehjopen/oeag173
Primary Topic
Antiplatelet Therapy and Cardiovascular Diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Comparative Efficacy and Safety of De-escalation, Abbreviation, and Standard Potent P2Y12 Inhibitor–Based Dual Antiplatelet Therapy Strategies After Acute Coronary Syndrome: A Network Meta-Analysis

Chi‐Sheng Hung, Yen‐Hung Lin, Hungju Lin, Yee-Jen Wu et al.
European Heart Journal Open
Antiplatelet Therapy and Cardiovascular Diseases
article

Comparative Efficacy and Safety of De-escalation, Abbreviation, and Standard Potent P2Y12 Inhibitor–Based Dual Antiplatelet Therapy Strategies After Acute Coronary Syndrome: A Network Meta-Analysis

Chi‐Sheng Hung, Yen‐Hung Lin, Hungju Lin, Yee-Jen Wu, Yi-Chen Chou
article en

Abstract

Abstract Background Potent P2Y12 inhibitor–based dual antiplatelet therapy (DAPT) is the default antiplatelet strategy after acute coronary syndrome (ACS), though de-escalation to clopidogrel-based DAPT and abbreviated DAPT followed by potent P2Y12 inhibitor monotherapy are increasingly adopted to mitigate bleeding risk. However, their relative efficacy and safety remain uncertain. Methods Network meta-analyses of randomized controlled trials were performed to compare three guideline-endorsed strategies: (1) short-term potent P2Y12 inhibitor–based DAPT de-escalation to clopidogrel-based DAPT, (2) Abbreviated DAPT followed by potent P2Y12 inhibitor monotherapy, and (3) standard 12-month potent P2Y12 inhibitor–based DAPT. Primary efficacy endpoint was major adverse cardiovascular events (MACE). Secondary efficacy endpoints included all-cause mortality, cardiovascular mortality, myocardial infarction, stent thrombosis, and stroke. Primary safety endpoint was major bleeding. The key net clinical endpoint was net adverse clinical events (NACE). PROSPERO (CRD420251144892) Results Seven randomized controlled trials involving 20,673 patients were included. Both the de-escalation and abbreviation strategies significantly reduced major bleeding (RR 0.43, 95% CI 0.25-0.74, p=0.002; and RR 0.43, 95% CI 0.33-0.58, p<0.001, respectively) and NACE (RR 0.54, 95% CI 0.41-0.70, p<0.001; and RR 0.72, 95% CI 0.61-0.84, p<0.001, respectively) without increasing MACE or other ischemic outcomes. Indirect comparison indicated that de-escalation vs abbreviation strategies demonstrated comparable MACE, NACE and bleeding outcomes. Conclusions Following ACS, both de-escalation to clopidogrel-based DAPT and abbreviated DAPT followed by potent P2Y12 inhibitor monotherapy effectively reduce bleeding risk without compromising ischemic protection. Given that the only available comparison between the two simplified strategies was indirect and showed comparable MACE and NACE outcomes, further research is warranted to determine the optimal individualized approach.

European Heart Journal Open
National Taiwan University Hospital (TW)
Openalex Percentile: Top 12%
Antiplatelet Therapy and Cardiovascular Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.